Literature DB >> 25461526

Development of an improved live attenuated antigenic marker CSF vaccine strain candidate with an increased genetic stability.

L G Holinka1, I Fernandez-Sainz2, B Sanford3, V O'Donnell4, D P Gladue5, J Carlson6, Z Lu7, G R Risatti8, M V Borca9.   

Abstract

Controlling classical swine fever (CSF) involves vaccination in endemic regions and preemptive slaughter of infected swine herds during epidemics. Live attenuated marker vaccines that confer effective protection against the disease and allow differentiation between infected and vaccinated animals (DIVA) could impact CSF control policies. Previously, we reported the development of FlagT4 virus (FlagT4v), a rationally designed live attenuated marker vaccine. During its vaccine assessment, FlagT4v reverted to a virulent virus during successive passages in piglets. Sequence analysis revealed deletions and substitutions almost exclusively in the areas of E1 and E2. To improve genetic stability of FlagT4v, we introduced changes in the codon usage in those areas. The newly developed virus, FlagT4Gv, was shown to retain the attenuated phenotype after successive passages in piglets. As observed with FlagT4v, the newly developed FlagT4Gv conferred effective protection against challenge with virulent CSFV at early (7 days) and at late (28 days) times post-vaccination. Published by Elsevier Inc.

Entities:  

Keywords:  Classical swine fever virus; DIVA strategy; Marker vaccine; Minimal protective dose; Protection; Vaccine safety

Mesh:

Substances:

Year:  2014        PMID: 25461526     DOI: 10.1016/j.virol.2014.09.021

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Early protection events in swine immunized with an experimental live attenuated classical swine fever marker vaccine, FlagT4G.

Authors:  Lauren G Holinka; Vivian O'Donnell; Guillermo R Risatti; Paul Azzinaro; Jonathan Arzt; Carolina Stenfeldt; Lauro Velazquez-Salinas; Jolene Carlson; Douglas P Gladue; Manuel V Borca
Journal:  PLoS One       Date:  2017-05-24       Impact factor: 3.240

Review 2.  Research Progress and Challenges in Vaccine Development against Classical Swine Fever Virus.

Authors:  Qiang Wei; Yunchao Liu; Gaiping Zhang
Journal:  Viruses       Date:  2021-03-10       Impact factor: 5.048

Review 3.  The Development of Classical Swine Fever Marker Vaccines in Recent Years.

Authors:  Fangfang Li; Bingke Li; Xinni Niu; Wenxian Chen; Yuwan Li; Keke Wu; Xiaowen Li; Hongxing Ding; Mingqiu Zhao; Jinding Chen; Lin Yi
Journal:  Vaccines (Basel)       Date:  2022-04-13

4.  The FlagT4G Vaccine Confers a Strong and Regulated Immunity and Early Virological Protection against Classical Swine Fever.

Authors:  José Alejandro Bohórquez; Miaomiao Wang; Ivan Díaz; Mònica Alberch; Marta Pérez-Simó; Rosa Rosell; Douglas P Gladue; Manuel V Borca; Llilianne Ganges
Journal:  Viruses       Date:  2022-09-02       Impact factor: 5.818

5.  Impact of a Live Attenuated Classical Swine Fever Virus Introduced to Jeju Island, a CSF-Free Area.

Authors:  SeEun Choe; Jae-Hoon Kim; Ki-Sun Kim; Sok Song; Wan-Choul Kang; Hyeon-Ju Kim; Gyu-Nam Park; Ra Mi Cha; In-Soo Cho; Bang-Hun Hyun; Bong-Kyun Park; Dong-Jun An
Journal:  Pathogens       Date:  2019-11-20

6.  Genetically distinct pestiviruses pave the way to improved classical swine fever marker vaccine candidates based on the chimeric pestivirus concept.

Authors:  Alexander Postel; Paul Becher
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

7.  Development of a Dendrimeric Peptide-Based Approach for the Differentiation of Animals Vaccinated with FlagT4G against Classical Swine Fever from Infected Pigs.

Authors:  José Alejandro Bohórquez; Sira Defaus; Rosa Rosell; Marta Pérez-Simó; Mònica Alberch; Douglas P Gladue; Manuel V Borca; David Andreu; Llilianne Ganges
Journal:  Viruses       Date:  2021-10-02       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.